Healthcare · Biotechnology
Price
$0.37
Market Cap
$3.3M
Employees
11
Beta
0.61
Avg Volume
11,106,296
CEO
Lance Alstodt
Business Description
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.23
Stock Price: $0.37
EPS (Diluted): -1.58
EPS (Diluted): -1.58
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
29.75
Stock Price: $0.37
Total Equity: $356,744
Shares: 8,993,115
Total Equity: $356,744
Shares: 8,993,115
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.02
Market Cap: $3.32M
Total Debt: $0.00
Cash: $1.51M
EBITDA: -$14.03M
Total Debt: $0.00
Cash: $1.51M
EBITDA: -$14.03M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$9.1M
Market Cap: $3.32M
Total Debt: $0.00
Cash: $1.51M
Total Debt: $0.00
Cash: $1.51M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
29.50
Stock Price: $0.37
Revenue: $359,700
Shares: 8,993,115
Revenue: $359,700
Shares: 8,993,115
EV/Sales (Total value vs revenue — works when P/E can't)
API25.30
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
93.4%
Gross Profit: $335,856
Revenue: $359,700
Revenue: $359,700
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-4,350.1%
Operating Income: -$15.65M
Revenue: $359,700
Revenue: $359,700
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-3,959.4%
Net Income: -$14.24M
Revenue: $359,700
Revenue: $359,700
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-423.8%
Net Income: -$14.24M
Total Equity: $356,744
Total Equity: $356,744
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-464.9%
Operating Income: -$15.65M
Tax Rate: 0.0%
Equity: $356,744
Total Debt: $0.00
Cash: $1.51M
Tax Rate: 0.0%
Equity: $356,744
Total Debt: $0.00
Cash: $1.51M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.84
Current Assets: $3.14M
Current Liabilities: $3.72M
Current Liabilities: $3.72M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $356,744
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $356,744
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.04
Revenue: $359,700
Shares: 8,993,115
Shares: 8,993,115
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.04
Total Equity: $356,744
Shares: 8,993,115
Shares: 8,993,115
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.21
Operating CF: -$10.79M
CapEx: -$116,069
Shares: 8,993,115
CapEx: -$116,069
Shares: 8,993,115
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.37
Stock Price: $0.37
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$14.24M
Net Income: -$14.24M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BRTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 2:59am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $46,000 | $119,800 | $145,800 | $401,000 | $359,700 |
| Cost of Revenue | $0 | $0 | $0 | $28,072 | $23,844 |
| Gross Profit | $46,000 | $119,800 | $145,800 | $372,928 | $335,856 |
| Operating Expenses | $26.4M | $19.0M | $15.4M | $11.9M | $16.0M |
| Operating Income | -$26.3M | -$18.9M | -$15.2M | -$11.6M | -$15.6M |
| Net Income | -$44.3M | -$13.2M | -$10.4M | -$9.0M | -$14.2M |
| EBITDA | -$42.4M | -$13.1M | -$15.0M | -$8.8M | -$14.0M |
| EPS | $-37.30 | $-3.65 | $-2.47 | $-1.16 | $-1.58 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 2:59am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.0M | $1.7M | $884,377 | $547,890 | $1.5M |
| Total Current Assets | $21.5M | $15.1M | $11.4M | $11.1M | $3.1M |
| Total Assets | $22.5M | $16.4M | $12.6M | $12.3M | $4.1M |
| Current Liabilities | $363,822 | $6.0M | $2.6M | $3.7M | $3.7M |
| Long-Term Debt | $191,030 | $0 | $0 | $0 | $0 |
| Total Liabilities | $856,497 | $6.1M | $2.6M | $3.7M | $3.7M |
| Total Equity | $21.6M | $10.3M | $10.0M | $8.5M | $356,744 |
| Retained Earnings | -$134.1M | -$136.3M | -$146.7M | -$155.7M | -$169.9M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 2:59am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M | -$5.9M | -$6.4M | -$8.2M | -$10.8M |
| Capital Expenditure | $-30,658 | $-440,223 | $-171,043 | $-106,189 | $-116,069 |
| Free Cash Flow | -$3.4M | -$6.4M | -$6.6M | -$8.3M | -$10.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $18.0M | -$19.3M | $-829,395 | $-336,487 | $963,298 |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:09am (5h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.3M $1.5M – $3.1M
|
$3.1M $2.0M – $4.2M
|
$118.7M $77.7M – $159.7M
|
$139.2M $91.2M – $187.2M
|
| EBITDA |
-$2.3M -$3.1M – -$1.5M
|
-$3.1M -$4.2M – -$2.0M
|
-$118.7M -$159.7M – -$77.7M
|
-$139.2M -$187.2M – -$91.2M
|
| Net Income |
-$3.6M -$5.3M – -$2.0M
|
-$3.7M -$4.4M – -$3.0M
|
$16.1M $8.9M – $23.4M
|
$17.3M $9.5M – $25.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 2:59am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +160.4% | +21.7% | +175.0% | -10.3% |
| Gross Profit Growth | +160.4% | +21.7% | +155.8% | -9.9% |
| Operating Income Growth | +28.3% | +19.3% | +24.1% | -35.4% |
| Net Income Growth | +70.2% | +21.2% | +13.8% | -58.6% |
| EBITDA Growth | +69.1% | -14.3% | +41.3% | -59.6% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:09am (5h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Grasso Mika | 0.00 | $0.00 | $0 | |
| 2026-06-10 | Dhaliwal Jatinder | 0.00 | $0.00 | $0 | |
| 2026-06-10 | Field Katharyn | 0.00 | $0.00 | $0 | |
| 2025-10-06 | Silva Francisco | A-Award | 11,719.00 | $1.60 | $18,750 |
| 2025-10-06 | Silva Francisco | A-Award | 11,719.00 | $2.75 | $32,227 |
| 2025-10-06 | ALSTODT LANCE | A-Award | 15,625.00 | $1.60 | $25,000 |
| 2025-10-06 | ALSTODT LANCE | A-Award | 11,719.00 | $2.75 | $32,227 |
| 2025-02-14 | Rosa David A | A-Award | 52,632.00 | $2.46 | $129,475 |
| 2025-02-14 | Williams Patrick F. | A-Award | 52,632.00 | $2.46 | $129,475 |
| 2025-02-14 | Kukekov Nickolay V. | A-Award | 52,632.00 | $2.46 | $129,475 |
| 2025-02-14 | Kristal Robert Eugene | A-Award | 166,492.00 | $2.46 | $409,570 |
| 2025-02-14 | Silva Francisco | A-Award | 768,979.00 | $2.46 | $1.9M |
| 2025-02-14 | ALSTODT LANCE | A-Award | 791,885.00 | $2.46 | $1.9M |
| 2024-10-28 | Broadrick Dale | S-Sale | 1,112.00 | $1.58 | $1,757 |
| 2024-04-09 | Silva Francisco | P-Purchase | 6,600.00 | $1.25 | $8,250 |
| 2024-04-08 | Silva Francisco | P-Purchase | 1,232.00 | $1.17 | $1,441 |
| 2024-04-08 | Silva Francisco | P-Purchase | 476.00 | $1.13 | $538 |
| 2024-03-18 | Silva Francisco | F-InKind | 17,193.00 | $1.39 | $23,898 |
| 2024-03-18 | ALSTODT LANCE | F-InKind | 17,633.00 | $1.39 | $24,510 |
| 2024-02-13 | Rosa David A | A-Award | 79,646.00 | $1.45 | $115,487 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for BRTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for BRTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30